REGN News

Key Factors

Recent Updates

Catalyst

Strong cash reserves and favorable operating cash flow suggest solid financial health for REGN.

Risk

Recent technical indicators show a weak market with bearish signals dominating, indicating a high risk of decline.
Analyst ratings are divided, with no clear consensus, which may reflect uncertainty about REGN's outlook.

Generated at22:5103/24/2026by

Aime

Newswire

14:28

Regeneron Secures Approval for First Targeted Bullous Pemphigoid Therapy in Japan

09:53

Regeneron's 15min chart triggers RSI Overbought, KDJ Death Cross signal.

02:42

Sanofi's Dupixent approved in Japan to treat moderate-to-severe bullous pemphigoid.

02:03

Sanofi and Regeneron's Dupixent Approved in Japan for Bullous Pemphigoid Treatment

02:01

Sanofi and Regeneron's Dupixent Approved in Japan for Moderate to Severe Bullous Pemphigoid Treatment

About REGN

Charts

SectorBiological Technology

Established Date--

Listing Date05/04/1991

ExchangeNASDAQ Stock Exchange

Full-time Employees15410

Fiscal Year Ends31/12

Websitewww.regeneron.com

Security TypeCommon stock

Office address777 Old Saw Mill River Road, Tarrytown, New York 10591-6707

BusinessProduction and sales of pharmaceutical products

Introduction

Regeneron Pharmaceuticals, Inc. was incorporated in New York State in 1988. The company is a fully integrated biotechnology company that invents, develops, manufactures and commercializes medicines for people with serious diseases. Its core business strategy is built on a strong foundation of scientific research and proprietary technology, advancing a diverse portfolio of products and product candidates across multiple therapeutic areas.